Abstract: The present application n relates to a pharmaceutical composition comprising a PD-1 antibody and an M-CSF antibody. The combination can be administered independently or separately, in a quantity which is therapeutically effective for the treatment of cancer.

Abstract: The invention provides methods for treating neurological diseases and reducing microglia density using anti-IL-34 antibodies.

Abstract: IL-6 antagonists are provided that are specific for binding to site II of IL-6. Methods of using such inhibitors to treat IL-6 related diseases, e.g., disease of the eye such as diabetic macular edema are disclosed.

Abstract: The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (ASIC1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, ASIC1-mediated ion currents in cells expressing human ASIC1. The antibodies of the invention are useful for the treatment of pain, including pain associated with surgical intervention and various diseases and disorders.

Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.

Abstract: Agents that specifically bind to a muscarinic acetylcholine receptor in a conformationally specific way can be used to induce a conformational change in the receptor. Such agents have therapeutic applications and can be used in X-ray crystallography studies of the receptor. Such agents can also be used to improve drug discovery via compound screening and/or structure based drug design.

Abstract: The present disclosure provides antibodies and antibody drug conjugates that bind human CS1 and their uses to treat subjects diagnosed with a plasma cell neoplasm, for example, multiple myeloma.

Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Abstract: Combination therapies comprising antibody molecules that specifically bind to PD-1 disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.

Abstract: Provided herein are the use of FGFR3 inhibitors and taxanes to treat solid and hematologic cancers, as well as compositions and kits comprising an FGFR3 inhibitor and a taxane.

Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.

Abstract: The present invention relates to anti-CSF-1R induced lymphocytosis in lymphomas and leukemias and a combination therapy of antibodies which bind human CSF-1R with antibodies which bind human CD20.

Abstract: The present inventors used a model of intrasplenically induced liver metastasis to determine whether or not NF-?B activation in the liver is involved in the onset of metastatic tumors. When IKK? was deleted from both liver cells and hematopoietically-derived cells, the onset of tumors was reduced remarkably. Tumor cells activated neighboring bone marrow cells (Kupffer cells) and produced mitogens such as interleukin (IL)-6, and this promoted angiogenesis and growth of tumors. The mitogen production depended on NF-?B in hematopoietically-derived Kupffer cells. Furthermore, treatment with an anti-IL-6 receptor antibody decreased the degree of metastatic tumor development. That is, the present inventors showed that tumor metastasis depends on inflammation, and proinflammatory intervention that targets Kupffer cells is useful for chemical prevention of metastatic tumors.

Abstract: The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.

Abstract: A therapeutic agent for chronic arthritides diseases of childhood-related diseases, for example chronic arthritides diseases of childhood, Still's disease and the like, comprising an interleukin-6 (IL-6) antagonist as an active ingredient.

Abstract: Disclosed herein are combinations of an OX40 modulator and a PD-1 modulator, pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said combination, including uses in cancer.

Abstract: Disclosed herein are combinations of an OX40 modulator and a CTLA-4 modulator, pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said combination, including uses in cancer.

Abstract: An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.

Abstract: Herein are provided bispecific anti-human A-beta/human transferrin receptor antibodies and methods of using the same.

Abstract: Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.

Abstract: There is provided an anti-human CRTH2 antibody which has desired activity by recognizing and binding to a specific human CRTH2; the antibody fragment; DNA which encodes the amino acid sequence of the antibody; a vector which comprises the DNA; hybridomas and antibody producing cells which produce the antibody; a method of producing the antibody; a composition which comprises the antibody or the antibody fragment; a treatment method and a diagnostic method of an allergic disease, an autoimmune disease, a disease accompanied by at least one of increase and hyperergasia of eosinophils; a disease accompanied by at least one of increase and hyperergasia of Th2 cells using the antibody or the antibody fragment; and a medicine and a diagnostic agent which comprise the antibody or the antibody fragment.

Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ.

Abstract: Certain embodiments are directed to a bispecific immunoglobulin that is capable of binding cell surface molecules on a target cell, such as cancer cells, and cell surface molecules on immune effector cell, such as cytotoxic T lymphocytes, resulting in the targeted killing of target cells.

Abstract: An isolated antibody that specifically binds to an extracellular domain of two or more human FZD receptors and inhibits growth of tumor cells is described. Also described is a method of treating cancer comprising administering an antibody of the present disclosure in an amount effective to inhibit tumor cell growth.

Abstract: The present describes monoclonal antibody to MUC1*.

Abstract: The present disclosure provides humanized antibodies, including antibodies comprising an ultralong CDR3 and uses thereof.

Abstract: The present invention is directed to novel heterodimeric antibodies.

Abstract: The present invention relates to a method for preparing a polysaccharide comprising a step of the polymerization of a saccharide monomer by non-thermal plasma treatment.

Abstract: Poly alpha-1,3-glucan ether compounds are disclosed herein comprising positively charged organic groups. The degree of substitution of the ether compounds is about 0.05 to about 3.0. Also disclosed are methods of producing poly alpha-1,3-glucan ether compounds having positively charged organic groups, as well as methods of using these ether compounds for increasing the viscosity of a aqueous compositions. Hydrocolloids and aqueous solutions comprising the ether compounds are also disclosed.

Abstract: The present invention relates to dimeric pentadentate chelators with exceptionally strong binding of metal ions, for detection, immobilization and purification of biomolecules. Dimeric chelators offer a cooperativity of binding of two adjacent immobilized metal ions simultaneously to a histidine-tagged biomolecule, which gives advantageous properties regarding strength of binding compared to a corresponding monomer chelator. In addition, a dimer increases the selectivity (ease of separation) against non-tagged biomolecules with low metal-ion affinity.

Abstract: The present invention provides a method for producing polyisoprene including the steps of: (A) combining a plant tissue containing polyisoprene with an organic solvent at a temperature of 60 to 80° C. to prepare a polyisoprene solution; and (B) lowering the temperature of the polyisoprene solution to 0 to 30° C. to deposite the polyisoprene in the polyisoprene solution, wherein the organic solvent is ethylene glycol dimethyl ether.

Abstract: Catalyst compositions based on Ruthenium- or Osmium-based complex catalysts and specific co-catalysts are provided for selectively hydrogenating nitrile rubbers in the presence of such catalyst compositions.

Abstract: The present invention provides a modifier including a silane-based compound of Formula 1, which may prevent the agglomeration of a filler in a rubber composition and increase the dispersibility of a filler, thereby improving the processability of a rubber composition, by easily introducing a functional group having affinity with a filler into a conjugated diene-based polymer chain, and a modified and conjugated diene-based polymer prepared using the same.

Abstract: Disclosed herein are processes for preparing functionalized polymers, functionalizing compounds useful in the processes and processes for preparing the functionalizing compound. The processes for preparing a functionalized polymer include reaction of a functionalizing compound (prepared from the reaction of an alkoxysilane compound of formula (I) with a polyol of formula (II)) with a reactive conjugated diene monomer-containing polymer, thereby producing a polymer end functionalized with the functionalizing compound. In certain embodiments, the functionalizing compound has a formula according to formula (III), (IV), or (V).

Abstract: A conjugated diene-based polymer comprising a structural unit derived from a conjugated diene compound and having, at a terminal of the polymer, at least one nitrogen-containing group represented by formula (1) is used. In formula (1), R1 is a hydrocarbyl group, and the symbol “*” is a bonding site.

Abstract: Provided is an olefin-based polymer with excellent processability. The olefin-based polymer according to the present invention has a high molecular weight and a broad molecular weight distribution to show excellent processability and improved mechanical properties, thereby being usefully applied according to the intended use.

Abstract: The present invention relates to a novel ligand compound represented by Formula 1 and a novel transition metal compound represented by Formula 2, and the novel ligand compound and transition metal compound according to the present invention has high comonomer incorporation effect in the preparation of an olefinic polymer having a low density and a high molecular weight, and thus can be usefully used as a catalyst for a polymerization reaction.

Abstract: Copolymers of a polyvinyl butyral backbone with polylactic acid grafts and their compounds are disclosed, which can be used to produce clear, flexible and ductile bio-based films. The copolymers are amorphous and have been shown to maintain clarity, flexibility, and ductility after continuous exposure to thermal aging at 80° C. for one week.

Abstract: The invention provides polymers having the structure: wherein Q, Q?, E, R1, a, b, c, d, and n are described herein. The invention further provides compositions comprising the polymers such as, personal care, hair care, coatings, and battery compositions. The invention furthermore provides hair care compositions comprising the polymers described herein.

Abstract: The present invention relates to a polypropylene having excellent stiffness and achieving energy reduction during foaming.

Abstract: The present invention provides a polypropylene-based composite material capable of exhibiting excellent strength properties and impact strength properties, particularly, markedly improved impact strength properties at a low temperature without using a separate additive by including (A) polypropylene, and (B) an olefin-based polymer which satisfies the conditions of the following (b1) to (b4): (b1) density (d): from 0.850 to 0.910 g/cc, (b2) melt index (MI, 190° C., 2.16 kg load conditions): from 0.1 g/10 min to 100 g/10 min, (b3) molecular weight distribution (MWD): from 1.5 to 3.0, and (b4) i) two peaks are shown in a temperature range of ?20° C. to 120° C. when taking measurements of temperature rising elution fractionation, and ii) a relation of T(90)?T(50)?60° C. is satisfied (where T(90) is a temperature at which 90 wt % of the olefin-based polymer is eluted, and T(50) is a temperature at which 50 wt % of the olefin-based polymer is eluted).

Abstract: Particles of an acrylic polymer comprising a constituent unit (A) derived from methyl methacrylic acid and a constituent unit (B) derived from a (meth)acrylic acid alkyl ester in which the alkyl group has 2 to 8 carbon atoms, wherein the particles having electrostatic buildup inhibition rate of 90 to 99.9%.

Abstract: The disclosed technology relates to pure polyitaconic acid homo- and co-polymers free of the less reactive tri-substituted vinyl monomers (e.g., citraconic acid or mesaconic acid) that may be used, for example, as builders in detergent applications, such as in the personal and home care market.

Abstract: Polyisobutylenes (PIBs) containing a high proportion of vinylidene end groups are generally favored over conventional PIBs because of their higher reactivity in reactions that are needed to prepare fuel and lubricant additives. However, detergent additives that have been prepared from conventional PIBs actually perform better than detergent additives prepared from high reactive PIBs. Specifically, detergent additives that were prepared from conventional PIB that was then enriched with tri- and tetra-PIB resulted in altered thermal stability and improved detergency of the resulting compound as compared to the structures which were created using a high proportion of vinylidene end groups.

Abstract: The present invention relates to an ethylene polymer comprising moieties according to formula (I): wherein R is a moiety comprising ?1 and ?10 carbon atoms; wherein the ethylene polymer has a molecular weight distribution of ?3.0 and ?13.0; the ethylene polymer has a melting temperature of ?115° C.; the ethylene polymer has a density ?935 and ?960 kg/m3; the ethylene polymer is essentially free from chromium, hafnium, zirconium and tetrahydrofuran; for the fraction of the ethylene polymer having a molecular weight ?100 kg/mol, the intrinsic viscosity of the ethylene polymer is related to the molecular weight according to the inequality: log I. V. <0.65*log M?3.10 Such polymers have high density, high purity and good processability, whilst maintaining barrier properties for oxygen and water vapour at a level similar to high-density polyethylenes produced via catalytic processes.

Abstract: The present invention relates to a process for the production of ethylene polymers in a tubular reactor comprising reacting in said tubular reactor a feed composition comprising ethylene and one or more composition comprising one or more cyclic olefin wherein the cyclic olefin is a compound having the structure of Formula (I): wherein R may be a moiety comprising ?1 and ?10 carbon atoms; wherein R1 and R2 may each individually be hydrogen or a moiety comprising ?1 and ?5 carbon atoms, R1 and R2 may be the same or different; wherein ? the tubular reactor may be operated at a pressure of ?200 and ?280 MPa; ? the average reaction peak temperature may be ?220° C. and ?300° C.; ? the composition comprising one or more cyclic olefin may be fed to the reactor in one or more feed inlet of said tubular reactor; and ? said cyclic olefin may be fed to the tubular reactor in quantities of ?1.0 mol %, with regards to the total feed composition.

Abstract: A system and method for charging a chromium-based catalyst to a mix vessel; introducing a reducing agent through an entrance arrangement into the mix vessel, and agitating a mixture of the chromium-based catalyst, the reducing agent, and a solvent in the mix vessel to promote contact of the reducing agent with the chromium-based catalyst to give a reduced chromium-based catalyst.

Abstract: A system and method for feeding a chromium-based catalyst to a polymerization reactor; adding a reducing agent to the chromium-based catalyst, and polymerizing an olefin into a polyolefin in the polymerization reactor in the presence of the chromium-based catalyst.

Abstract: Branched ethylene-propylene-diene elastomers (bEPDM) and processes for making the bEPDM's comprising combining a catalyst precursor and an activator at a temperature within a range from 90° C. to 160° C. with ethylene, a C3 to C12 ?-olefin, a non-conjugated diene, and a dual-polymerizable diene, where the catalyst precursor is a metallocene catalyst precursor, preferably according to one of various structures including any two ligands selected from cyclopentadienyl ligands and ligands isolobal to the cyclopentadienyl group.